Table 2. Univariate survival analyses in all patients and in patients treated with R-CHOP and R-CHOEP.
| R-CHOP | R-CHOEP | TOTAL | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFS | OS | PFS | OS | PFS | OS | |||||||||||||||||
| n | HR | 95% CI | p | HR | 95% CI | p | n | HR | 95% | p | HR | 95% | p | n | HR | 95% | p | HR | 95% | p | ||
| SEX | F | 24 | 2.3 | 1.0–5.2 | 0.03 | 3.2 | 1.1–9.5 | 0.026 | 21 | 1.5 | 0.47–5.0 | 0.5 | 0.98 | 0.26–3.6 | 1.0 | 45 | 2.2 | 1.2–4.3 | 0.01 | 2.20 | 1.0–4.8 | 0.04 |
| M | 39 | 19 | 58 | |||||||||||||||||||
| aaIPI | 2 | 49 | 2.1 | 0.97–4.5 | 0.05 | 3.9 | 1.7–9.2 | 0.001 | 31 | 0.79 | 0.17–3.7 | 0.8 | 1.0 | 0.20–4.9 | 1.0 | 80 | 1.5 | 0.78–3.1 | 0.2 | 2.6 | 1.2–5.4 | 0.009 |
| 3 | 14 | 9 | 23 | |||||||||||||||||||
| Age | Age ≤ 55 | 36 | 0.73 | 0.36–1.5 | 0.4 | 1.1 | 0.46–2.5 | 0.9 | 32 | 4.9 | 1.5–16 | 0.004 | 7.5 | 2.0–28.3 | 0.001 | 68 | 1.4 | 0.75–2.6 | 0.3 | 2.0 | 0.98–4.0 | 0.05 |
| Age > 55 | 27 | 8 | 35 | |||||||||||||||||||
| FISH | MYC + | 6 | * | * | * | * | * | * | 7 | * | * | * | * | * | * | 13 | 0.60 | 0.21–1.7 | 0.3 | 0.63 | 0.19–2.1 | 0.4 |
| MYC - | 55 | 31 | 86 | |||||||||||||||||||
| BCL6 + | 17 | 1.3 | 0.62–2.8 | 0.5 | 1.6 | 0.68–3.9 | 0.3 | 10 | 1.8 | 0.53–6.2 | 0.3 | 1.6 | 0.40–6.4 | 0.5 | 27 | 1.4 | 0.77–2.4 | 0.3 | 1.6 | 0.79–3.4 | 0.2 | |
| BCL6 - | 44 | 28 | 72 | |||||||||||||||||||
| BCL2 + | 17 | 0.83 | 0.37–1.9 | 0.7 | 0.52 | 0.18–1.5 | 0.2 | 12 | 0.81 | 0.22–3.1 | 0.8 | 0.59 | 0.12–2.8 | 0.5 | 29 | 0.8 | 0.41–1.6 | 0.5 | 0.5 | 0.22–1.3 | 0.2 | |
| BCL2 - | 44 | 26 | 70 | |||||||||||||||||||
| DH MYC + BCL2/BCL6 + | 3 | * | * | * | * | * | * | 5 | * | * | * | * | * | * | 8 | 0.50 | 0.12–2.0 | 0.4 | 0.33 | 0.045–2.4 | 0.2 | |
| IHC | BCL2 > 85% | 35 | 2.7 | 1.2–5.8 | 0.01 | 2.5 | 0.96–6.3 | 0.05 | 22 | 1.1 | 0.32–3.4 | 0.9 | 1.0 | 0.28–3.9 | 0.9 | 57 | 2.0 | 1.1–3.9 | 0.03 | 1.9 | 0.9–4.0 | 0.09 |
| BCL2 ≤ 85% | 28 | 18 | 46 | |||||||||||||||||||
| BCL2 > 70% | 42 | 2.8 | 1.1–6.8 | 0.02 | 2.7 | 0.9–7.9 | 0.07 | 26 | 2.9 | 0.62–13 | 0.2 | 2.1 | 0.44–10 | 0.3 | 68 | 2.8 | 1.3–6.1 | 0.005 | 2.5 | 1.0–6.1 | 0.04 | |
| BCL2 ≤ 70% | 21 | 14 | 35 | |||||||||||||||||||
| MYC > 75% | 11 | 3.3 | 1.5–7.3 | 0.002 | 1.7 | 0.61–4.5 | 0.3 | 10 | 0.62 | 0.14–2.9 | 0.5 | 0.82 | 0.17–3.9 | 0.8 | 21 | 1.6 | 0.82–3.2 | 0.2 | 1.2 | 0.52–2.8 | 0.7 | |
| MYC ≤ 75% | 52 | 30 | 82 | |||||||||||||||||||
| MYC > 40% | 32 | 1.4 | 0.71–2.9 | 0.3 | 1.2 | 0.51–2.7 | 0.7 | 26 | 0.54 | 0.16–1.8 | 0.3 | 0.58 | 0.16–2.2 | 0.4 | 58 | 0.96 | 0.52–1.7 | 0.9 | 0.90 | 0.44–1.8 | 0.8 | |
| MYC ≤ 40% | 31 | 14 | 45 | |||||||||||||||||||
| DE MYC > 40% + BCL2 > 70% | 26 | 1.7 | 0.85–3.4 | 0.1 | 1.2 | 0.54–2.9 | 0.6 | 17 | 0.73 | 0.21–2.5 | 0.6 | 0.64 | 0.16–2.6 | 0.5 | 43 | 1.3 | 0.72–2.4 | 0.4 | 1.0 | 0.50–2.1 | 1.0 | |
| DE MYC > 75% + BCL2 > 85% | 10 | 4.4 | 2.0–9.8 | <0.001 | 1.9 | 0.72–5.3 | 0.2 | 9 | 0.31 | 0.040–2.4 | 0.4 | 0.40 | 0.050–3.2 | 0.4 | 19 | 1.7 | 0.83–3.4 | 0.15 | 1.1 | 0.47–2.8 | 0.8 | |
| GCB | 30 | 1.0 | 0.52–2.1 | 0.9 | 1.2 | 0.50–2.7 | 0.7 | 24 | 2.0 | 0.60–6.5 | 0.3 | 2.1 | 0.56–7.7 | 0.3 | 54 | 1.3 | 0.74–2.4 | 0.3 | 1.5 | 0.72–2.9 | 0.3 | |
| Non-GCB | 33 | 16 | 49 | |||||||||||||||||||
| GCB + DE MYC > 75% + BCL2 > 85% | 6 | 8.7 | 2.8–27 | <0.001 | 2.4 | 0.61–9.2 | 0.2 | 8 | 0.48 | 0.054–4.3 | 0.5 | 0.65 | 0.067–6.2 | 0.7 | 14 | 2.0 | 0.79–5.0 | 0.1 | 1.3 | 0.40–4.0 | 0.7 | |
| GCB—DE MYC > 75% + BCL2 > 85% | 24 | 16 | 40 | |||||||||||||||||||
| Non-GCB + DE MYC > 75% + BCL2 > 85% | 4 | * | * | * | * | * | 0.5 | 1 | * | * | * | * | * | * | 5 | 1.8 | 0.53–6.0 | 0,4 | 1.3 | 0.31–5.9 | 0.7 | |
| Non-GCB—DE MYC > 75% + BCL2 > 85% | 29 | 15 | 44 | |||||||||||||||||||
R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOEP, rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone; PFS, progression free survival, OS, overall survival; HR, Hazard ratio; 95%CI, 95% confidence interval; F, female; M, male; aaIPI, age-adjusted international prognostic index; FISH, fluorescent in situ hybridization; IHC, immunohistochemistry; GCB, germinal center B-cell like.
* too few patients for meaningful statistical analyses.